RxDoctor Payments Data

Richard Syfert, DO

Family Medicine · Davenport, IANPI 1881690709

Payments from drug & device makers

$1,119in general payments, 2019–2025

Across 88 payments — averaging $12.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$221
  • AstraZeneca$178
  • Pfizer$164
  • Boehringer Ingelheim$138
  • AbbVie$129
  • Phathom Pharmaceuticals, Inc.$104
  • plus $185 from 5 others

What the payments were for

  • Food & beverage$1,11399%
  • Education$61%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,119 in reported general payments places this provider in the 80th percentile of 1,357 family medicine providers in Iowa.

See all family medicine providers in Iowa

Medicare billing

Part B allowed, 2024
$42,867
Medicare patients
191
Services billed
406

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban45$40,713
OzempicSemaglutide12$20,739
JardianceEmpagliflozin24$17,396
TradjentaLinagliptin17$16,909
XareltoRivaroxaban11$10,562
Lantus SolostarInsulin Glargine,hum.Rec.Anlog34$3,665
Humalog Kwikpen U-100Insulin Lispro19$3,548
Atorvastatin Calcium237$2,170
Levothyroxine Sodium213$1,563
Potassium Chloride46$1,417
Albuterol Sulfate HfaAlbuterol Sulfate48$1,244
Lisinopril187$1,168
Simvastatin194$1,129
Amlodipine Besylate179$1,070
Omeprazole116$1,013

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$164$40,71345 claims
Boehringer IngelheimJardiance, Tradjenta$138$34,30541 claims
Novo NordiskOzempic$221$20,73912 claims
Johnson & JohnsonXarelto$49$10,56211 claims
AbbVieSynthroid$129$57111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,357 family medicine providers in Iowa.

Other family medicine in Davenport

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →